



Innovative Medicines Initiative (IMI) **– Info Day in POLAND**

Gdańsk

September 25th, 2012

Drug discovery in the life of the human being


„The unprecedented increase in human life expectancy, which has almost doubled in a hundred years, is mainly due to drugs and to those who discovered them.”



**Alfred Burger
1905-2000**

“The great advances of medicinal chemistry have been achieved by two types of investigators:

- Those with the **genius**, who have opened a new field by interpreting correctly a few well-placed experiments
- And those who have **changed patiently** the chemical structures of physiologically active compounds until drug could be evolved as a new tool in medicine.”




Drug

1. Effectiveness
2. Safety



Drug Discovery Process



Drug Discovery Process

Success, Bottlenecks, and the Future of Antimicrobial Drug Discovery

acswebinars




Unskrybuj

188 filmów

Drug Discovery & Development

- Risky, Long, Expensive

Figure 1.3: From Laboratory to Patient: The Complex Pathway of Biopharmaceutical R&D



- On average: 12-15 yrs, \$800+MM; ~40% of the time is discovery
- (Need to be better than average!)

27

Pharmaceutical Industry Profile 2005 <http://www.pbrma.org/>



21:57 / 59:03



[http://www.imi.europa.eu/content/
documents](http://www.imi.europa.eu/content/documents)



**Only one drug candidate
in 10 000 makes it to the patient**



Find out how IMI will change that



Innovative Medicines Initiative

EARLY ACHIEVEMENTS

SEPTEMBER 2011

IMI supports projects in the following pre-competitive areas:

- ❑ **Predicting safety**
- ❑ **Predicting efficacy**
- ❑ **Knowledge management**
- ❑ **Education and training**

Indicative topics of the 4th Calls for Proposals were:

- ❑ **EU medical information system**
- ❑ **Chemistry, manufacturing and control**
- ❑ **Technology and molecular disease understanding**


Conference agenda

10.00–10.30	Registration
10.30–10.45	Welcome – Prof. Tomasz Bączek, Vice Rector of Science (MUG)
10.45–11.15	Innovative Medicines Initiative – about IMI and future calls – Prof. Michel Goldman, Executive Director, IMI
11.15–11.45	IMI: a public-private partnership success story – Magdalena Chlebuz, Director Science Policy, EFPIA
11.45–12.15	Practical and legal/financial advices for IMI application/participation – Magali Poinot, IMI Office Brussels
12.15–12.45	Coffee break
12.45–13.15	Support for potential participants in health and health-related calls – Anna Pytko, National Contact Point for Research Programmes of the EU
13.15–13.45	What IMI means for Poland – Prof. Maciej Bagiński, Gdańsk University of Technology, Deputy to Polish Representative of SRG IMI
13.45–14.15	Krzysztof Łoboda, M.D. – IMI participant from Jagiellonian University in Kraków, Medical College
14.15–14.45	INFARMA – the Employers' Union of Innovative Pharmaceutical Companies in Poland
14.45–15.15	Discussion

Innovative Medicines Initiative (IMI)

- ❑ IMI is a joint undertaking between the **European Union** and the **European Federation of Pharmaceutical Industries and Associations (EFPIA)**.
- ❑ The Innovative Medicines Initiative (IMI) is revolutionizing the way pharmaceutical research is being done, by offering **a new and unique model for public-private collaboration**.
- ❑ IMI aims to **speed up the development of safer and more effective medicines** for patients.

A TYPICAL IMI CONSORTIUM



Conference agenda

10.00–10.30	Registration
10.30–10.45	Welcome – Prof. Tomasz Bączek, Vice Rector of Science (MUG)
10.45–11.15	Innovative Medicines Initiative – about IMI and future calls – Prof. Michel Goldman, Executive Director, IMI
11.15–11.45	IMI: a public private partnership success story – Magdalena Chlebus, Director Science Policy, EFPIA
11.45–12.15	Practical and legal/financial advices for IMI application/participation – Magali Poinot, IMI Office Brussels
12.15–12.45	Coffee break
12.45–13.15	Support for potential participants in health and health-related calls – Anna Pytko, National Contact Point for Research Programmes of the EU
13.15–13.45	What IMI means for Poland – Prof. Maciej Bagiński, Gdańsk University of Technology, Deputy to Polish Representative of SRG IMI
13.45–14.15	Krzysztof Łoboda, M.D. – IMI participant from Jagiellonian University in Kraków, Medical College
14.15–14.45	INFARMA – the Employers' Union of Innovative Pharmaceutical Companies in Poland
14.45–15.15	Discussion

IMI currently funds 23 ongoing projects with a total budget of €453 million, involving:

- ❑ 221 **R&D teams** from EFPIA **companies**;
- ❑ 298 **academic**-type institutions;
- ❑ 47 small and medium-sized **enterprises**;
- ❑ 11 **patients'** organizations;
- ❑ 7 **regulatory** agencies.

Conference agenda

10.00–10.30	Registration
10.30–10.45	Welcome – Prof. Tomasz Bączek, Vice Rector of Science (MUG)
10.45–11.15	Innovative Medicines Initiative – about IMI and future calls – Prof. Michel Goldman, Executive Director, IMI
11.15–11.45	IMI: a public private partnership success story – Magdalena Chlebus, Director Science Policy, EFPIA
11.45–12.15	Practical and legal/financial advices for IMI application/participation – Magali Poinot, IMI Office Brussels
12.15–12.45	Coffee break
12.45–13.15	Support for potential participants in health and health-related calls – Anna Pytko, National Contact Point for Research Programmes of the EU
13.15–13.45	What IMI means for Poland – Prof. Maciej Bagiński, Gdańsk University of Technology, Deputy to Polish Representative of SRG IMI
13.45–14.15	Krzysztof Łoboda, M.D. – IMI participant from Jagiellonian University in Kraków, Medical College
14.15–14.45	INFARMA – the Employers' Union of Innovative Pharmaceutical Companies in Poland
14.45–15.15	Discussion

Innovative Medicines Initiative (IMI)

"By linking the best academic teams with high-level industry scientists, IMI is building the research capacity needed to cure the major diseases of our time."

Michel Goldman, IMI Executive Director